Inhibikase Therapeutics, Inc. Common Stock (IKT) is a publicly traded Healthcare sector company. As of September 22, 2026, IKT trades at $2.21 with a market cap of $320.93M and a P/E ratio of -5.20. IKT moved -4.35% today. Year to date, IKT is +7.32%; over the trailing twelve months it is +34.15%. Its 52-week range spans $1.33 to $3.32. Analyst consensus is strong buy with an average price target of $6.40. Rallies surfaces IKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for IKT shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $2.21 |
| Market Cap | $320.93M |
| P/E Ratio | -5.20 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.32 |
| 52-Week Low | $1.33 |
| Volume | 301.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.72M |
| Net Income | $-60.64M |
| Gross Margin | 0.00% |
5 analysts cover IKT: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.40.